You are here

Clinical update

The concept of treatment-free remission in CML

sandy craine's picture
Submitted by sandy craine on Thu, 04/08/2016 - 4:35pm

The advent of tyrosine kinase inhibitors (TKI) into the management of patients with chronic myeloid leukemia (CML) has profoundly improved prognosis. Survival of responders is approaching that of the general population but lifelong treatment is still recommended. In several trials, TKI treatment has been stopped successfully in approximately half of the patients with deep molecular response. This has prompted the development of a new concept in the evaluation of CML patients known as ‘treatment-free remission’.

Dasatinib in imatinib resistant or intolerant chronic phase Chronic Myeloid Leukaemia patients: 7-year follow-up of study CA180-034

sandy craine's picture
Submitted by sandy craine on Mon, 18/07/2016 - 8:33pm

Neil P. Shah,1* Philippe Rousselot,2 Charles Schiffer,3 Delphine Rea,4 Jorge E. Cortes,5 Jorge Milone,6 Hesham Mohamed,7 Diane Healey,7 Hagop Kantarjian,5 Andreas Hochhaus,8 and Giuseppe Saglio,9

Dasatinib was approved at 100 mg once daily for imatinib-resistant or -intolerant patients with chronicmyeloid leukemia (CML) in chronic phase, based on results of the phase 3 CA180-034 (NCT00123474) study. Here we present the final 7-year analysis of this pivotal study, the longest follow-up to date of any second-generation BCR–ABL1 tyrosine kinase inhibitor (TKI).

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

sandy craine's picture
Submitted by sandy craine on Thu, 05/05/2016 - 3:12pm

A Hochhaus, G Saglio, T P Hughes, R A Larson, D-W Kim, S Issaragrisil, P D le Coutre, G Etienne, P E Dorlhiac-Llacer, R E Clark, I W Flinn, H Nakamae, B Donohue, W Deng, D Dalal, H D Menssen and H M Kantarjian

Abstract

TKIs in CML Linked With Vascular Events

sandy craine's picture
Submitted by sandy craine on Sat, 20/02/2016 - 5:40pm

Treatment with the BCR-ABL tyrosine kinase inhibitors (TKIs) dasatinib, nilotinib, and ponatinib was associated with increased risk for vascular occlusive events in patients with chronic myeloid leukemia (CML) compared with imatinib, according to the results of a meta-analysis published in JAMA Oncology.

At 5 Years, Nilotinib Offers Benefit Over Imatinib in CML

sandy craine's picture
Submitted by sandy craine on Thu, 11/02/2016 - 5:45pm

Five-year results of the randomised phase III ENESTnd trial show a positive risk-benefit profile for nilotinib in patients with chronic myeloid leukaemia (CML) in chronic phase (CP), as compared to imatinib. Cardiovascular risk does seem to be slightly raised with nilotinib, but improvements in CML disease control likely outweigh those risks. -

Pages